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Abstract
We present a case of a 54‐year‐old male with multiple myeloma (MM) who
presented with widespread pruritic erythematous lesions following ixazomib
treatment. This occurred after his third cycle of treatment with ixazomib,
thalidomide and dexamethasone and was controlled by potent steroids and
temporary cessation of ixazomib. The strong correlation between the
timeline of the rash, ixazomib treatment and subsequent cessation led to a
diagnosis of a drug‐induced rash. Skin biopsy histology, immunochemistry
and the absence of monoclonal T‐cell receptor gene rearrangement further
confirmed the diagnosis of a T‐cell pseudolymphoma secondary to ixazo-
mib. Ixazomib is an oral proteasome inhibitor used in the treatment of MM.
Other proteasome inhibitors have been reported to trigger cutaneous
adverse effects. However, to our knowledge, this is the first report of
pseudolymphoma following proteasome inhibitor use. Dermatologists
should be aware of this potential effect and the possible management
pathways such as cessation and dose reduction.
A 54‐year‐old black British male developed multiple
painful, pruritic lesions which became widespread over
5 days, starting on his face, progressing to trunk and
limbs. He had no associated systemic symptoms. He
was diagnosed with multiple myeloma (MM) in 2012.
After initial treatment response, relapse in 2018 was
managed with four cycles of ixazomib, thalidomide and
dexamethasone (ITD), with a plan for subsequent stem
cell transplantation. The rash developed during the third
cycle of ITD, following his ninth dose of ixazomib.
Additional past medical history included discoid lupus
erythematosus and extensive idiopathic vitiligo.
On examination, there were multiple, tender,
discrete 0.5–1 cm indurated erythematous papules
and nodules over his neck, finger, leg, back and trunk
(Figure 1).
Skin biopsy demonstrated an atypical angiocentric
lymphoid infiltrate throughout the dermis, extending
into subcutaneous fat (Figure 2). Immunochemistry
confirmed T‐cell lineage, predominantly CD8 positive.
Stains for CD20, CD30, anaplastic lymphoma kinase,
epithelial membrane antigen and EBV encoded small
RNA for Epstein–Barr virus were negative. No mono-
clonal T‐cell receptor gene rearrangement was seen,
which combined with the strong temporal correlation of
the rash with treatment, made T‐cell lymphoma un-
likely. Staining to exclude a gamma delta lymphoma
and EBV screen were negative.
Ixazomib was temporarily stopped and super‐potent
topical steroids and chlorpheniramine administered.
Improvement occurred within 7 days of ixazomib
cessation and resolution within 13 days, at which point
ixazomib was reintroduced with a 25% dose reduction.
Subsequent recurrenceof the rash occurred during cycle
4 of ITD after two further doses of ixazomib (at day 14),
which supported our suspicion that this was drug‐
induced, but as the rash was mild no additional dose
modification was required. He subsequently underwent
an autologous stem cell transplant and did not receive
further ixazomib. We concluded the lesions represented
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cutaneous T‐cell pseudolymphoma secondary to
ixazomib.
Cutaneous pseudolymphomas represent a rare
reactive process that involves lymphocytic infiltrates
which ultimately mimic cutaneous lymphomas. The in-
filtrate's imitation is based on clinical as well as histo-
pathological findings.1 The most common form of
cutaneous pseudolymphoma is nodular pseudolym-
phoma which consists of B‐cell, T‐cell and mixed
pseudolymphomas.1 Recognized triggers of cutaneous
pseudolymphomas include lymphomatoid drug re-
actions, lymphomatoid contact dermatitis and infections
including Borrelia‐associated T‐pseudolymphoma.1
Drugs known to cause cutaneous pseudolymphomas
include antihypertensive, anticonvulsants, anxiolytics
and antipsychotics.1 To our knowledge, this is the first
report of ixazomib triggering a T‐cell pseudolymphoma.
Ixazomib is an oral proteasome inhibitor (PI) used in
the treatment of MM.2 Reported toxicities include
thrombocytopenia, peripheral neuropathy and unclas-
sified rashes (seen in 36%).2 Ixazomib was reported to
cause cutaneous necrotizing vasculitis in one 66‐year‐
old with MM following 33 days of treatment.3 Here, af-
ter the second cycle, the patient developed multiple
urticated plaques, managed with temporary ixazomib
cessation followed by dose reduction. Similarities were
seen clinically between our patient and this 66‐year‐old
patient as both patients had similar looking purpuric
papules, with an almost urticarial appearance in simi-
larly situated areas of the body: neck, chest and back.
However, biopsies in this 66‐year‐old patient revealed a
mixed acute and chronic granulomatous necrotizing
vasculitis with eosinophils present as well as a vacuolar
interface dermatitis.3 Biopsies from our patient revealed
a more angiocentric lymphoid infiltrate that was present
in the dermis as well as the subcutaneous fat and had a
confirmed T‐cell lineage, hence histologically both
cases differ.
Older PIs also have reported cutaneous effects.
Bortezomib triggered a leukocytoclastic vasculitis in a
female patient with MM,4 responsive to corticosteroid
treatment, which recurred on drug reintroduction.
Additionally, during three phase II trials in patients with
non‐Hodgkin lymphoma, bortezomib was seen to cause
an erythematous maculopapular rash in 26 patients
over the three trials. Biopsies revealed a non‐
necrotising cutaneous vasculitis, with no evidence of
lymphoma and a perivascular lymphocytic infiltrate was
seen. In these cases, it was observed that the rash was
not dose‐dependent as patients on different doses over
the three trials developed the rash.5 In addition, another
case report of bortezomib‐induced leukocytoclastic
vasculitis was seen in a 55‐year‐old male with MM.6
This patient had similar findings to our patient, with
a purpuric rash starting on day 9 of the third cycle
of treatment and occurring on the patient's trunk,
back, extremities and face. However, a biopsy of
the rash showed leukocytoclastic vasculitis in the
dermis as well as extending into the superficial
subcutaneous fat with vessel wall destruction and
accumulation of inflammatory cells.6 Histologically
this differed from our presented case as a lymphoid
infiltrate of T‐cell lineage was seen on biopsy with
no vessel wall damage. It was also found that the
55‐year‐old male patient being treated with borte-
zomib had increased levels of tumour necrosis
factor alpha, interleukin 6 and C‐reactive protein in
his serum that researchers hypothesized may have
led to the bortezomib‐induced cutaneous leukocyto-
clastic vasculitis, which was not seen in our case.6
Interestingly, ixazomib is being trialled for systemic
lupus erythematosus (SLE), in the hope that via a
reduction in plasma cells, SLE autoantibodies will be
reduced.7 We are uncertain if our patient's autoimmune
comorbidities may have been relevant to developing
pseudolymphoma.
F I GURE 1 (a) Well‐circumscribed erythematous macules
which have a slightly targetoid appearance which measured 5–
10 mm. Papules can be seen on both the right side of the chest
as well as more indurated papules centrally, on a background
of widespread depigmentation due to long‐standing vitiligo.
(b) Lesion on the thigh with a central ulcerated dark erythematous
papule and surrounding erythema with induration
What is already known about this topic?
� Proteasome inhibitors have been reported to
cause cutaneous effects, such as leukocyto-
clastic vasculitis, in some patients.
� Cutaneous pseudolymphomas are rare and
have many potential causes.
What does this study add?
� To our knowledge, this is the first report of
cutaneous pseudolymphoma following pro-
teasome inhibitor use.
� Possible management of T‐cell pseudolym-
phoma via temporary cessation or dose
reduction techniques.
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This report summarizes a rare cutaneous drug re-
action to ixazomib. This is the first report of pseudo-
lymphoma with PIs. Dermatologists should be aware of
this due to the increasing use of PIs, and management
options include temporary cessation or dose reduction.
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F I GURE 2 (a) Histology: H&E stain shows a vessel surrounded by large, atypical lymphoid cells in an angiocentric pattern. The
endothelium of the vessel is very swollen indicating early vascular damage, which combined with the atypical lymphoid infiltrate imitates an
angiocentric lymphoma hence the term angiocentric pseudolymphoma. Level of magnification: �20 objective magnification. (b) H&E stain
shows a smaller vessel showing vascular damage. Level of magnification: �20 objective magnification. (c) Low‐power H&E stain showing a
superficial and deep infiltrate within the dermis and subcutis. H&E, haematoxylin and eosin
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